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Subcellular localizationAMP-activated protein kinase (AMPK) and cytosolic brain-type creatine kinase (BCK) cooperate under energy
stress to compensate for loss of adenosine triphosphate (ATP) by either stimulating ATP-generating and
inhibiting ATP-consuming pathways, or by direct ATP regeneration from phosphocreatine, respectively. Here
we report on AMPK-dependent phosphorylation of BCK from different species identiﬁed by in vitro screening
for AMPK substrates in mouse brain. Mass spectrometry, protein sequencing, and site-directed mutagenesis
identiﬁed Ser6 as a relevant residue with one site phosphorylated per BCK dimer. Yeast two-hybrid analysis
revealed interaction of active AMPK speciﬁcally with non-phosphorylated BCK. Pharmacological activation of
AMPK mimicking energy stress led to BCK phosphorylation in astrocytes and ﬁbroblasts, as evidenced with a
highly speciﬁc phospho-Ser6 antibody. BCK phosphorylation at Ser6 did not affect its enzymatic activity, but
led to the appearance of the phosphorylated enzyme at the endoplasmic reticulum (ER), close to the ER calcium
pump, a location known for muscle-type cytosolic creatine kinase (CK) to support Ca2+-pumping.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
A key element in sensing energy stress at the cellular and whole-
body level is AMP-activated protein kinase (AMPK). This evolutionary
conserved, heterotrimeric serine/threonine kinase integrates various
inputs on the energy and nutritional state to ﬁnally trigger a large
variety of cellular responses to relieve energy stress (reviewed ininoimidazole carboxamide ri-
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icht University, Maastricht, The[1–4]). AMPK is activated covalently by phosphorylation of its α-
subunit at Thr172 under the control of different upstream kinases and
phosphatases that convey regulation by e.g. Ca2+ and various
hormones. During energy stress, AMPK is activated by increased levels
of AMP and also ADP [4–7] binding to the γ-subunit. They act via direct
allosteric activation, promotion of phosphorylation at Thr172 and
inhibition of dephosphorylation by phosphatases, involving a con-
formational switch as shown by us and others [8–10].
Activated AMPK directly acts on enzymes to regulate metabolic
pathways or other signaling cascades, or to activate transcription factors
for long term adaptation of energy metabolism. AMPK has further
functions beyond energy homeostasis, e.g. in controlling cell cycle,
shape, motility and proliferation (reviewed in [2,3]). Its involvement
in metabolic and proliferation signaling proposed the kinase as a phar-
macological target for type II diabetes and cancer (reviewed in [11–14]).
Isoforms of creatine kinase (CK) are essential parts of an intricate
cellular energy buffer and transport system based on creatine (Cr) and
phosphocreatine (PCr) that has been described in much detail by us
and others [15–19]. Cellular uptake of Cr is controlled by a speciﬁc
transporter [20]. CK then catalyzes the reversible transfer of high-
energy phosphates between ATP and Cr to yield ADP and the high
energy intermediate phosphocreatine (PCr). In cells with elevated and
variable energy demands, in particular in muscle and brain, the CK
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homeostasis [15,17,19]. CK isoforms accumulate PCr within the cell to
high concentrations (up to 15 mM in brain) and use this otherwise
inert compound in the reverse reaction to regenerate global and local
ATP pools under conditions of increased workload (energy buffer func-
tion). They also exploit the rapid diffusibility of PCr to connect cellu-
lar sites of ATP generation (e.g.mitochondria) with sites of high ATP
consumption (e.g.myoﬁbrils or ion pumps; energy shuttle function).
To fulﬁll these speciﬁc cellular functions, CK isoforms do not behave
as strictly soluble enzymes, but partially associate with deﬁned cel-
lular structures. Based on the X-ray structures of banana-shaped cy-
tosolic CK dimers and cuboidal octameric mitochondrial CK
isoenzymes (MtCK) solved by us and others [21–24], the functioning
of this membrane bound CK has been elucidated in molecular detail.
MtCK co-localizes with mitochondrial adenylate translocase in
proteolipid complexes to access matrix ATP for efﬁcient PCr genera-
tion [15,25,26]. Cytosolic muscle-type CK (MCK) interacts with pro-
teins in the myoﬁbrillar M-line (myomesin, M-protein) and co-
localizes with the sarcoplasmic/endoplasmic reticulum calcium
pump (Ca2+-ATPase, SERCA) to sustain massive, local regeneration
of ATP from PCr for muscle contraction and Ca2+-pumping, respec-
tively [27,28]. In these cases, microcompartments are formed that
allow direct channeling of ATP from CK to associated ATPases [28,
29].
Much less is known in this respect for the cytosolic brain-type CK
(BCK) found in the brain andmost other non-muscle tissues. There is
evidence from knockout mice and subcellular localization studies
that the energy buffer and transport functions of the CK system are
required to support high ATP turnover and correct functioning of
brain cells. Knockout mice lacking BCK and brain MtCK (uMtCK)
show a marked cognitive phenotype with deﬁciencies in learning
and memory [30], spatial orientation [31], and in the functioning of
hair bundle cells in the auditory system [32]. In the latter case, BCK
allows for the very high ATP turnover (1 mM/s) imposed by the plas-
ma membrane Ca2+-ATPase pump to maintain Ca2+-cycling. Like in
the case of MCK, speciﬁc subcellular localization of BCK may be nec-
essary for optimal local ATP supply. This notion is supported by co-
localization of BCK with actomyosin in cortical microdomains of as-
trocytes and ﬁbroblasts that affects cell shape and motility [33], or
with F-actin in macrophages at the nascent phagosome that contrib-
utes to early steps in phagocytosis [34]. However, it is unknown how
BCK is recruited to such speciﬁc cellular sites. That this may happen
via direct protein/protein interactions is suggested by a study on
thrombin signaling. Here, BCK directly interacts with the protein G-
coupled thrombin receptor PAR-1 to provide ATP for efﬁcient throm-
bin signaling and the associated cytoskeletal reorganization [35].
Whether such interactions are regulated remains an open question.
Although BCK phosphorylation events can be found in earlier litera-
ture [36–38], they lack essential data like their effect on enzyme
function and phosphorylation levels.
Functionally, the AMPK and CK systems cooperate in maintaining
energy homeostasis within a cell [39]. While the CK system can react
very rapidly to an acute energy challenge, AMPK is more involved in
medium and long-term adaptations. A cross-talk between both sys-
tems has been postulated, including MCK interaction with and phos-
phorylation by AMPK [40]. However, both, the reported inhibition of
MCK enzyme activity and, vice versa, AMPK-regulation by PCr/Cr ra-
tios [40] could not be conﬁrmed by follow-up studies [41–43]. Here
we report on a speciﬁc phosphorylation of the BCK isoform at Ser6
by different AMPK isoforms that involves only transient interaction
with AMPK. This phosphorylation does not affect enzymatic cataly-
sis, but leads to the appearance of phospho-BCK at the endoplasmic
reticulum (ER) and co-localization with the highly energy-
demanding ER Ca2+-pump. This is the ﬁrst example that AMPK-
mediated phosphorylation is not activating or inactivating an en-
zyme, but rather promoting a speciﬁc subcellular function.2. Material and methods
2.1. Proteins
Rabbit BCK puriﬁed from brainwas purchased from Sigma (St. Louis,
USA). Chicken BCK (b subtype, Bb-CK, GeneID: 396248) subcloned into
pET-3b (Novagen, Madison, USA), human BCK (GeneID: 1152)
subcloned into streptavidin-fusion vector derived from pET-52b(+)
(Novagen) and human BCK non-tagged subcloned into pET-42(+)
vector (Novagen) were expressed in bacteria and puriﬁed by two-step
chromatography as described earlier [21]. Site-directed mutagenesis
of hBCK was performed by PCR using Phusion DNA polymerase
(Finnzymes, Vantaa, Finland) and mutagenic primers. PCR products
were puriﬁed with Nucleo Spin Extract II (Macherey Nagel) and self-
ligated using T4 DNA ligase (New England Biolabs, Evry, France). All
constructs were veriﬁed by DNA sequencing. Wild-type (WT) AMPK
α1β1γ1 (111WT) and α2β2γ1 (221WT) isoform combinations, as
well as the corresponding constitutively active forms mutated at
αT172, α1T172Dβ1γ1 (111TD) or α2T172Dβ2γ1 (221TD) were
expressed in bacteria from polycistronic vectors and puriﬁed by multi-
dimensional HPLC as described earlier [8,44]. GST-CamKKβ fusion
from pGEX-PreS-CamKKβ (kindly provided by H. Tokumitsu, Kagawa
Medical University, Japan) and GST-ACC catalytic domain fusion
construct (kindly provided by G. Hardie, Univ. of Dundee, UK) were
expressed and puriﬁed as described earlier with some modiﬁcations
[45].2.2. Screening for AMPK substrates, mass spectrometry, Edman sequencing
Screening was performed according to the ‘MudSeeK’ protocol (38)
with a modiﬁed protein pre-fractionation. Brieﬂy, mouse brain lysates
(180 mg protein, dialyzed against 10 mM HEPES, pH 8.5, 5% glycerol)
were separated on an anion exchange column (Poros HQ, 4.67 ml bed
volume, Life Technologies, Carlsbad, USA) with a linear salt gradient
(0–1 M NaCl, 10 mM HEPES, pH 8.5). Protein in selected fractions was
precipitated by stepwise addition of saturated ammonium sulfate solu-
tion (10% steps to 70% (v/v)). Each pellet was resuspended in 250–400
μl 20 mM HEPES pH 8 by vortexing and sonication for 5 min and salt
removed by overnight dialysis against 20 mM HEPES pH 8. Resulting
fractions were subjected to 1D- and 2D-screening as described [46].
Untagged hBCK was phosphorylated in vitro by constitutively active
α1T172Dβ1γ1 AMPK (111TD), separated by SDS-PAGE, stained with
colloidal Coomassie Blue, and radioactive gel bands excised. Tryptic
digestion, peptide extraction, puriﬁcation by reverse-phase chromatog-
raphy and mass spectrometric analysis were performed as reported
[47]. Selected radioactive peptides were sequenced by solid phase
Edman degradation [48].2.3. In vitro phosphorylation assays
In vitro phosphorylation of BCK was carried out as described [49,
50]. Brieﬂy, 240 pmol protein was incubated for 3 min at 37 °C in the
presence or absence of 10 pmol AMPK 111TD in kinase buffer con-
taining 200 μM [γ-32P]ATP (with a speciﬁc activity of 400 mCi/
mmol ATP), 50 μM AMP, 5 mM MgCl2, 1 mM DTT, and 10 mM
HEPES (pH 7.4). Alternatively, wild-type (WT) α1β1γ1 or α2β2γ1
AMPK (111WT, 221WT) was activated by 20 min incubation at
30 °C with 1 pmol CamKKβ in kinase buffer without radiolabel. BCK
WT or mutants (200 pmol) were incubated for 3 min at 37 °C
in the presence or absence of 3.5 pmol pre-activated 111WT or
221WT in kinase buffer. Kinase reactions were stopped by the addi-
tion of SDS sample buffer. Aliquots (9 μg protein) were subjected to
10% SDS-PAGE and autoradiography or analysis with a Typhoon
phosphoimager (GE Healthcare, Vélizy, France).
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Enzymatic activity of puriﬁed hBCK wild-type and mutants was
measured with a photometer using a coupled enzyme assay as
described for forward and reverse reactions [51]. Changes in the redox
state of pyridine nucleotides were followed at 340 nm in a Specord
210 spectrophotometer (Analytikjena, Jena, Germany) thermostated
at 25 °C. For the determination of dissociation rate constants (Kd, Km),
a matrix of initial velocity data was recorded by varying 5 different
concentrations of each substrate at 5 different, ﬁxed concentrations of
the second substrate (0.5, 1, 2, 4 and 20 mM PCr; 0.02, 0.1, 0.2, 0.4 and
2.0 mM ADP; 0.5, 1, 2, 5 and 10 mM Cr; 0.1, 0.2, 0.8, 2 and 4 mM ATP).
Mg salt concentrations were chosen to assure that ADP and ATP are
entirely in their Mg2+-complexed form. Data were analyzed by global
ﬁtting with a random equilibrium model (Sigma Plot Enzyme Kinetics
Module). Gel ﬁltration chromatography of pure BCK WT and mutant
proteins was done with Superose 12 columns (GE Healthcare)
and 25 mM Tris–HCl (pH 8.0), 150 mM NaCl and 2 mM β-
mercaptoethanol at 1.0 ml/min and 10 °C. The column was calibrated
for Stokes' radii with carbonic anhydrase (24.0 Å, 29 kDa), albumin
(35.5 Å, 67 kDa), aldolase (48.1 Å, 158 kDa), catalase (52.2 Å,
232 kDa), ferritin (61 Å, 440 kDa) and thyroglobulin (70.0 Å, 669 kDa).
2.5. Yeast two-hybrid assays
Interaction of hBCK WT and S6D mutant with different AMPK
subunits was analyzed by a cytosolic Y2H technique based on reconsti-
tution of split-ubiquitin (cyto-Y2H, Dualsystems Biotech, Schlieren,
Switzerland; [52]). Cloning procedures using Sﬁ1 sites, transformation
of yeast cell line NMY51 and yeast spotting were performed as
described [52]. The systemwasmodiﬁed for anchoring interaction part-
ners at the plasmamembrane, not at the ER (unpublished data). Brieﬂy,
BCKs were expressed as plasma membrane-anchored fusion proteins
(bait), while AMPK subunits were expressed as soluble fusion proteins
(prey). Interactions activating reporter gene transcription allow growth
on nutrient-deﬁcient medium. Yeast cells were spotted on selective
medium lacking tryptophan and leucine (SD-WL) as growth assay to
verify the presence of bait and prey plasmid, and on medium lacking
tryptophan, leucine, adenine and histidine (SD-AHWL) for protein
interaction analysis. Spotted plates were incubated 72 h at 30 °C.
2.6. Cell culture and treatments
Primary astrocyte cultures were prepared aseptically from the
cerebral hemispheres of three- to four-day-old mice pups as described
previously [53] with some modiﬁcations. Pups were sacriﬁced by
decapitation under sterile conditions. Cerebral hemispheres were
dissected free of the meninx and gently dispersed in DMEM/F12
supplemented with 10% inactivated fetal calf serum and 1% penicillin,
streptomycin and amphotericin B. The resulting cell suspension was
centrifuged at 180 g for 5 min. The pellet was redispersed in the same
serum-supplemented medium and ﬁltered successively through cell
strainers with 100 μm and 70 μm pores. The ﬁnal concentration of the
cell suspension was adjusted to 6 × 105 cells per milliliter of medium.
The suspension was transferred into Petri dishes or glass coverslips
coated with poly-L-lysine (10 μg/ml). Cells were maintained at a con-
stant temperature of 37 °C in a humidiﬁed atmosphere containing 5%
CO2/95% air. Twenty-four hours after seeding, the culture medium was
removed and replaced with fresh medium. Medium was changed
every three days. Growth, density, and morphologic characteristics of
the cells were observed regularly by phase-contrast microscopy. After
10 to 12 days in culture, the cells were shaken in order to eliminate
microglia and oligodendrocytes. After 14 days in vitro (14 DIV), the
monolayer typically consisted of more than 95% astrocytes, as demon-
strated by positive immunostaining with the astrocyte marker glial
ﬁbrillary acidic protein (GFAP).Mouse embryonic ﬁbroblasts (MEFs), both WT and BAK−/− (BCK/
AK1 double knockoutMEFs) kindly provided by BéWieringa (Universi-
ty of Nijmegen, The Netherlands), were cultured as described [33].
When cultures were close to conﬂuence (about 3 days of culture),
they were treated for 30 or 60 min at 37 °C with 50 μM A-769662
(kindly provided by Grahame Hardie, Division of Molecular Physiology,
College of Life Sciences, University of Dundee, UK) or 1 mM amino-
imidazole carboxamide ribonucleotide (AICAR, Biotrend Chemicals,
Zurich, Switzerland), dissolved in DMSO or water, respectively.
2.7. Immunoblotting, 2D-PAGE and cellulose polyacetate electrophoresis
Cortical astrocyte lysates were prepared as described [33] using
lysis buffer containing protease inhibitor cocktail (Roche Diagnos-
tics, Mannheim, Germany) and phosphatase inhibitor cocktail (GE
Healthcare). Protein concentrations were determined with the
Bradford-based Biorad microassay (Biorad, Reinach, Switzerland)
and BSA as standard. Samples were resolved by 10% SDS-PAGE or
2D-PAGE and transferred to Hybond ECL nitrocellulose membrane
(Amersham Biosciences, Buckinghamshire, UK). Membranes were
washed 3× in Tris-buffered saline with 0.1% Tween-20 (TBST),
incubated in TBST with 5% nonfat dry milk (TBST-M) for 1 h at
room temperature (RT), washed again 3× in TBST, and incubated
with the following primary antibodies diluted in TBST-M for 1 h at
RT or overnight at 4 °C (if not stated otherwise, antibodies were
from Cell Signaling Technology, Danvers, MA, USA): rabbit poly-
clonal antibodies against P-Thr172 AMP-activated protein kinase
alpha (1:1000), P-Ser79 acetyl-CoA carboxylase (1:1000), total
AMP-activated protein kinase alpha (1:1000), total BCK (1:2000;
see [54]), and P-Ser6 BCK (1:1000). The anti-P-Ser6 BCK antibody
was obtained by immunization of rabbits with the synthetic peptide
PFSN(P~S)HNALKL (Eurogenetec, Angers, France), corresponding
to the very N-terminal part of hBCK (amino acids 1–12), and afﬁnity
puriﬁcation using the peptide employed for immunization.
Membranes were washed 3× in TBST and then incubated in a
TBST-M dilution of secondary antibodies coupled to horseradish
peroxidase for 1 h at RT (1:5000). After 3× washing in TBST,
immunoreactive bands were visualized by chemiluminescence (ECL
plus, Amersham Biosciences, Buckinghamshire, UK) using ﬁlm or
quantiﬁed by an ImageQuant LAS4000 (GE Healthcare).
For 2D-PAGE, cortical astrocytes were lysed in 7 M urea, 2 M
thiourea, 4% CHAPS, 40 mM DTT, 1.0% v/v IPG buffer, 0.5% v/v Triton
X-100, protease inhibitor mix (Roche Diagnostics, Mannheim,
Germany) and phosphatase inhibitor cocktail (GE Healthcare), soni-
cated, incubated for 1 h, centrifuged at 14,000 g for 60min, and desalted
with 2-D clean-up kit (GE Healthcare), all at 4 °C. Protein was deter-
mined with the 2D-Quant kit (GE Healthcare). About 500 μg protein
was separated on an Ettan IPGphor 3 (GE Healthcare) with nonlinear
gradient gel strips (pH 3–10, 24 cm; GE Healthcare) and 64,500 Vh (0
to 10,000 V during 12 h, constant voltage for 4 h). Strips equilibrated
in 75 mM Tris–HCl pH 8.8, 6 M urea, 29.3% glycerol, 2% SDS, and
0.002% bromophenol blue (in the presence of 1% DTT (w/v) or 2.5%
iodoacetamide (w/v), 15 min each) were applied to large 10% SDS-
PAGE gels. After protein separation and ﬁxation with 50% ethanol and
10% acetic acid for 1 h, gels were stained with colloidal Coomassie
Blue (Roth, Karlsruhe, Germany) for 12 h and excess dye was washed
out with distilled water.
For cellulose polyacetate electrophoresis (CPAE), astrocytes cultured
for 14 days were incubated in the presence or absence of 50 μM
A769662 for 30 min at 37 °C. Astrocyte lysates prepared as described
[33] were separated by CPAE for 1 h at 150 V and at room temperature
[55]. CPAE was performed on Cellogel strips (No. OlA42) in an electro-
phoresis tank (both from Biotec-Fischer, Reiskirchen, FRG) with run-
ning buffer (11.7 mM barbiturate, 52.4 mM diethylbarbiturate pH 8.6,
1.4 mM β-mercaptoethanol). CK bands were visualized by a color reac-
tion coupled to CK enzyme activity in an agarose overlay gel [55,56].
Fig. 1. BCK is phosphorylated by AMPK at serine 6. (A) Phosphorylation of BCK from different species. Autoradiograph (top) and Coomassie Blue stain (bottom, loading control) of SDS-
PAGE showing in vitro phosphorylated rabbit, human (Strep-tagged), and chicken BCK (240 pmol each), incubated with [γ-32P]ATP in the presence (+) or absence (–) of constitutively
activeα1T172Dβ1γ1 AMPK (111TD, 10 pmol). (B) Identiﬁcation of phospho-sites in human BCK (hBCK). Autoradiograph of solid phase Edman sequencing (seven cycles) identifying the
position of [γ-32P]-labeled amino acids in the two tryptic phosphopeptides (see Suppl. Fig. S1) isolated from hBCK phosphorylated as in panel A; membrane, residual peptide after last
Edman cycle; wash, unbound peptide. (C) Purity ofWT andmutant hBCK shown by Coomassie Blue-stained SDS-PAGE (5 μg protein/lane). (D) Ser6 is themain hBCK site phosphorylated
by AMPK. Autoradiograph (top) and Coomassie Blue stain (bottom, loading control) of SDS-PAGE showing in vitro phosphorylatedWT andmutant hBCK (200 pmol each) performed as in
panel A, but using AMPK α2β2γ1WT (221WT, 3.5 pmol) activated by CamKKβ (1 pmol). Note: only S6D mutation precludes phosphorylation by AMPK. (E) hBCK is phosphorylated by
AMPK111 and AMPK221. Autoradiograph and Coomassie Blue-stain of SDS-PAGE showing in vitro phosphorylatedWT and S6D hBCK (200 pmol each) performed as in panel D. (F) hBCK
and acetyl-CoA carboxylase (ACC) are phosphorylated at similar rates and stoichiometries. Autoradiograph and Coomassie Blue-stain of SDS-PAGE (top) showing in vitro phosphorylation
time course of GST-ACC (80 pmol) and hBCK monomers (200 pmol) performed as in panel D. Quantiﬁcation of incorporated radiolabel (bottom) is given as normalized to the protein
amount (intensity ratio) of ACC (○) or BCK (●) monomers, relative to the maximal ACC signal. (G) Phospho-mimetic hBCK mutants display slightly increased Stokes radius. Separation
ofWT andmutant hBCK (0.3mg each) on a calibrated Superose 12 column; elution volumes (Stokes radii) of BCKWT (black): 13.02ml (38.9 Å); S6D (gray): 12.92ml (39.7 Å); S6D–T35D
(DM, darkgray); 12.94ml (39.7 Å). Figures are representative of three repetitions. Abbr.: P-BCK, phospho-BCK; (P)AMPKα1, (P)AMPKβ1, autophosphorylatedAMPKα1- andβ1-subunits;
hBCK, human BCK; WT, wild-type; DM, S6D/T35D double mutant.
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Astrocytes grown on Lab-Tek chamber slides (Thermo Scientiﬁc
Nunc, Rochester, NY, USA) were treated with AMPK activators as
described above, rinsed twice with pre-warmed phosphate-buffered
saline (PBS), and ﬁxed with 3% paraformaldehyde in PBS. Following
three washing steps in PBS, cells were permeabilized with 0.2% Triton
X-100 in PBS. After extensive washing with PBS, cells were blocked for
1 h in PBS containing 3% bovine serum albumin (BSA) and 0.1% Tween20, incubated 1 h at RT or overnight at 4 °C with primary antibodies
diluted in blocking buffer, washed three times with blocking buffer
and incubated with secondary antibodies in blocking buffer for 45 min
at RT. Applied primary antibodies were rabbit anti-P-Ser6 BCK
(1:100), mouse anti-PDI (1:100, ER marker, Abcam, Cambridge, UK)
and chicken anti-BCK (1:200) [54]. Applied secondary antibodies were
DyLight 649 (red ﬂuorescence) conjugated either to goat–anti-rabbit
(1:250, Jackson ImmunoResearch, Baltimore, USA), donkey–anti-
mouse (1:250, Jackson ImmunoResearch), or donkey–anti-chicken
Table 1
Sequence alignment of BCK isoform species.
Sequence structure hhhhhhhh  hhhh                            hhhhh  hhhhh






Sequences are given for cytosolic BCKs from human (P12277, KCRB_HUMAN), mouse
(Q04447, KCRB_MOUSE), rat (P07335, KCRB_RAT), rabbit (P00567, KCRB_RABIT) and
chicken (P05122, KCRB_CHICK). Sequences of the proteins (with starting methionines
and targeting peptides) are given. The conserved secondary structure is indicated on top
(h, α-helix), residues homologous to Ser6 and Thr35 are indicated in bold letters.
Table 2
Enzyme kinetic constants of human BCK wild-type and S6D mutant.
Kinetic parameter hBCK proteins
WT S6D
Forward reaction
Speciﬁc activity [U/mg protein] 29.0 ± 2.9 29.5 ± 2.8
Kd (MgATP) [mM] 1.15 ± 0.05 1.11 ± 0.08
Km (MgATP) [mM] 0.88 ± 0.02 P0.86 ± 0.05
Kd (Cr) [mM] 6.94 ± 0.26 7.05 ± 0.11
Km (Cr) [mM] 5.80 ± 0.16 6.07 ± 0.10
Reverse reaction
Speciﬁc activity [U/mg protein] 128.0 ± 3.5 127.0 ± 5.2
Kd (MgADP) [mM] 0.19 ± 0.01 0.21 ± 0.02
Km (MgADP) [mM] 0.26 ± 0.01 0.29 ± 0.32
Kd (PCr) [mM] 1.99 ± 0.12 2.02 ± 0.17
Km (PCr) [mM] 3.10 ± 0.17 3.00 ± 0.05
Constants for the hBCKwild-type (WT) andmutant (nS6D) forward and reverse reactions
at pH 8 and 7, respectively, were calculated from initial rate data by global ﬁtting using
Sigma Plot software.
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ﬂuorescence) conjugated goat–anti-rabbit (1:250, Jackson Immuno-
Research). Different cellular structures (plasma membrane, Golgi)
were stained with 50 μg/μl of WGA (wheat germ agglutinin) directly
coupled to Alexa Fluor 350 (Invitrogen). Nuclei were stained with
1 μM Hoechst dye (Interchim, Montlucon, France) and mitochondria
with 250 nM Mitotracker Red CMXRos (Invitrogen) before perme-
abilization and immunostaining. Images were collected with a Leica
TCS SP2 Acoustico Optical Beam Splitter (AOBS) inverted laser scanning
confocal microscope equipped with a coherent 351–364 nm UV laser
using a 63× water immersion objective (HCX PL APO 63.0 × 1.20
water corrected). Laser excitation was 351/364 nm for Hoechst (nuclei)
andWGA, 488 nm for DyLight 488, 633 nm for DyLight 649 and 543 nm
for Mitotracker Red CMXRos and PLA probes. Confocal pinhole (Airy
units) was 1. Fluorescence emission bands were precisely adjusted
using an AOBS at 415–480 nm for Hoechst, 505–540 nm for Dylight
488, 645–705 nm for Dylight 649, 580–660 nm for Mitotracker Red,
and 575–655 nm for PLA-probes. In double staining of phospho-BCK
and PDI, confocal sections of 0.5 μm z-step of both ﬂuorescent signals
were acquired sequentially and thenmerged. 3D reconstruction images
were obtained using Volocity software (Improvision, France). Each
experiment was performed on a randomly chosen ﬁeld containing
several cells.2.9. Confocal 3D analysis and proximity ligation assay
A stack of nine confocal sections (z-series) was collected in 0.5 μm
steps. Each plane of the z-stacks was subjected to Image J software for
ﬂuorescence intensity analysis and Volocity software for ﬂuorescence
correlation analysis. Correlation between two ﬂuorescence channels is
represented in a scatter diagram (cytoﬂuorigram) of red voxels (y-
axis) co-localized with green voxels (x-axis). The calculated co-
localization coefﬁcient for both channels yields values between zero
(no co-localization) and one (complete co-localization) as described
[57].
Co-localization analysis in situ based on proximity ligation was per-
formedwith the Duolink In Situ kit (Olink Bioscience, Uppsala, Sweden)Fig. 2. BCKWT, not S6Dmutant, interacts with active AMPK in yeast-two-hybrid assays. Interact
was analyzed by a cytosolic split-ubiquitin yeast two-hybrid assay. Controls showhBCKdimeriz
T antigen (negative control). Spots represent yeast grown for 72 h at 30 °C. Growth media: sup
verifying the incorporation of bait and prey plasmids (growth) and bait/prey interaction (selecaccording to the manufacturer's instructions. This assay detects also
weak and transient interactions and co-localization with a maximum
distance of ~30 nm. Primary antibodies used were rabbit polyclonal
anti-P-BCK (diluted 1:100) andmousemonoclonal anti-SERCA2 (Pierce,
diluted 1:500).
2.10. Cellular subfractionation
Embryonic mouse ﬁbroblasts were lysed by extrusion via a 27 Ga
needle and ER-enriched fractions were obtained by using the
Endoplasmatic Reticulum isolation kit ER0100 (Sigma, St Louis, USA) ac-
cording to the manufacturer's instructions, following the calcium
precipitation method. Fractions were analyzed by immunoblotting
using primary antibodies speciﬁc against sarcoplasmic/endoplasmic
reticulum Ca2+-ATPase 2 (SERCA2, mouse monoclonal, Pierce, diluted
1:2500), the α1-subunit of Na+/K+-ATPase (mouse monoclonal;
Millipore, diluted 1:2500), total voltage-dependent anion channel
(VDAC, rabbit polyclonal, a gift of M. Colombini, Univ. Maryland, USA;
diluted 1:500) and chicken anti-BCK (1:200) [54]. For BCK detection,
identical aliquots of the post-mitochondrial fractions were in addition
calcium-precipitated to enrich for ER.
3. Results
3.1. BCK is phosphorylated by AMPK at Ser6
An in vitro screen to identify protein kinase targets, termed ‘MudSeeK’,
has been applied to identify new candidate AMPK substrate proteins from
mouse brain [46]. This approach combines multi-dimensional protein
prepuriﬁcation from brain extracts, in vitro phosphorylation assays, 2D-
PAGE and mass spectrometry. By adding a modiﬁed pre-fractionation
procedure involving ammonium sulfate precipitation, novel putative
AMPK targets have been detected and one of them identiﬁed as BCK. In
vitro phosphorylation assays with constitutive active α1T172Dβ1γ1ion of wild-type (WT) or S6D hBCKwith different AMPK subunits orαT172D (TD)mutant
ation (positive control) and lack of interactionwith an unrelated protein, Simian virus Large
plement-deﬁcient (SD) in adenine (A), histidine (H), tryptophan (W) or leucine (L) allow
tion).
Fig. 3.P-Ser6 BCK is detected in vitro and inmouse astrocytes by a speciﬁc antibody. (A) Speciﬁcity and afﬁnity of a purpose-madepolyclonal antibody raised against P-Ser6hBCK, testedby
immunoblots of phosphorylated hBCK (0.2–6.0 μg) using constitutive active αT172Dβ2γ1 AMPK (221TD) or of non-phosphorylated controls. Note: No detection of even 6 μg non-
phosphorylated hBCK. (B) Ser6-phosphorylation of murine BCK in primary mouse astrocytes, incubated for 30 min in DMED medium containing 50 μM A-769662 or vehicle only
(DMSO). Representative SDS-PAGE-immunoblot of total cell lysates (60 μg protein/lane) probed for phosphorylated and total protein as indicated. (C) Ser6-phosphorylation of murine
BCK in primarymouse astrocytes, incubated for 30min inmediumcontaining 1mMAICAR or vehicle only (dH2O). Upper panel: Representative SDS-PAGE-immunoblot of phosphorylated
acetyl-CoA carboxylase (P-Ser79 ACC) and AMPK (P-Thr172) in total cell lysates (60 μg protein/lane); Ponceau stain shown as loading control. Lower panel: Overlay of protein (Ponceau-
staining, red spots) and P-S6-BCK immunodetection (blue spots) in 2D-PAGE of total soluble protein (500 μg). (D) Enzyme activity of murine BCK is unaffected by Ser6-phosphorylation.
Upper panel: Native cellulose polyacetate electrophoresis (CPAE) of hBCK (1 μg) and lysates of primarymouse astrocytes (40 μg) incubated for 30min inDMEDmedium containing 50 μM
A769662 or vehicle only (DMSO). CK bandswere visualized by an enzyme-coupled assay that generates blue dye proportional to CK activity. Note: appreciation of BCK activity is achieved
by separation of BCK fromhighly homologousmitochondrial CK. Lower panel: SDS-PAGE-immunoblots for P-Ser6 BCK and P-T172 AMPKα from these astrocyte lysates. Note: BCK activity
is not affected by treatment with A769662; uMtCK bands migrate out of the gel. Figures are representative of three repetitions.
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BCK conﬁrmed that vertebrate BCK is a very good in vitro substrate for
AMPK (Fig. 1A).
To identify the involved residue(s), phosphorylated human BCK
(hBCK) was subjected to tryptic digest and HPLC separation (Suppl.
Fig. S1). The three radioactive fractions obtained (fractions 2, 10 and
35) were analyzed by MALDI-MS/MS, which revealed in two of them a
phosphopeptide due to the typical loss of a phosphoric acid moiety
(−98 Da; Suppl. Table 1 and Figs. S2, S3). Both peptides were in addi-
tion sequenced by Edman degradation, since there was some ambiguity
with two serines being present in one of them (Fig. 1B). This combined
approach identiﬁed two amino acids, Ser6 and Thr35, as putatively
phosphorylated residues. Both are located in the N-terminal small
domain of BCK; Ser/Thr residues at these positions are conserved across
vertebrate species (Table 1).
To verify phosphorylation at Ser6 and Thr35, both residues were
individually or together mutated into phospho-mimetic aspartic
acid. The single mutants S6D and T35D and double mutant S6D/T35D
(DM) were bacterially expressed, puriﬁed by two-step column
chromatography to high purity (Fig. 1C), and subjected to in vitrophosphorylation assays with wild-type α2β2γ1 AMPK (221WT) pre-
activated by the AMPK upstream kinase CamKKβ. While the T35D mu-
tant still became strongly phosphorylated, S6D and S6D/T35D mutants
incorporated only traces of radiolabel (Fig. 1D, left panels). Control
experiments showed that these in vitro phosphorylationswere only de-
pendent on the presence of AMPK, not CamKKβ (Fig. 1D, right panels).
Thus, Ser6 is the relevant AMPK phosphorylation site of hBCK.
Wild-type hBCK was phosphorylated by both AMPK complexes,
221WT and 111WT, when pre-activated with CamKKβ (Fig. 1G). The
ratio of 32P-incorporation into hBCK when incubated with the two
activated AMPK complexes (221WT/111WT) was 2.5 for hBCK and 1.5
for acetyl-coA carboxylase (ACC), an AMPK reference substrate,
suggesting hBCK to be a slightly better substrate for AMPK 221.
3.2. Ser6 is phosphorylated rapidly and at high levels comparable to ACC
The phosphorylation time course of hBCK WT and ACC, again using
AMPK 221WT pre-activated by CamKKβ, revealed a similar and very
rapid phosphorylation kinetics with half-maximal phosphorylation
below 3 min and a maximum attained after 15 min (Fig. 1F). The total
Fig. 4. Astrocyte P-Ser6 BCK localizes to perinuclear regions. Confocal microscopy images of primarymouse astrocytes ﬂuorescently labeled for BCK (red) and nuclei (blue). (A–C) P-Ser6
BCK, (D–F) P-Ser6 BCK in the presence of P-peptide used for generating the anti-P-Ser6 BCK antibody (competition assay as speciﬁcity control), or (G–I) total BCK. Asytocyteswere treated
for 30 min (A,D,G) with vehicle only (dH2O or DMSO) or with AMPK activators, either (B,E,H) 1 mM AICAR or (C,F) 50 μMA-769662. Scale bars: 47 μm (A–F) or 32 μm (G–I). Figures are
representative of at least three repetitions. Arrows: increased peri-nuclear staining in panels H and I.
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half of what is found with ACC. The ACC construct that we have been
using has only one AMPK phosphosite (Ser79) which can be almostFig. 5. P-Ser6 BCK is detectable upon AMPK activation in wild-type, but not BAK−/− ﬁbroblast
(A,B) control mice or (C,D) BAK−/− knockout mice, stained for P-Ser6 BCK (red) and nuclei (
activator A-769662 (50 μM). Scale bars: 35 μm (A–C) or 47 μm (D–F). Right panels: AMPK activ
analyzed by SDS-PAGE immunoblotting (40 μg protein/lane) for P-αThr172 AMPK. Figures arestoichiometrically phosphorylated [58]. Since native BCK occurs as
a dimer, the data suggest that one monomer per hBCK dimer is
phosphorylated.s. Confocal microscopy images of immortalizedmouse embryonic ﬁbroblasts (MEFs) from
blue). MEFs were treated for 30 min (A,C) with vehicle only (DMSO) or (B,D) with AMPK
ation in control or BAK−/−MEFs treated in the samemanner as above. MEF lysates were
representative of at least three repetitions.
Fig. 6.Astrocyte P-Ser6 BCK does not co-localizewithmitochondria or Golgi apparatus. Confocalmicroscopy images of primarymouse cortical astrocytes stained (A)withMitotracker Red
(mitochondrial marker, red ﬂuorescence), (B) for P-Ser6 BCK (green ﬂuorescence), (D) with wheat germ agglutinin (WGA, Golgi marker, blue ﬂuorescence), or (E) for P-Ser6 BCK (red
ﬂuorescence); (C,F) merged images. AMPK was activated by 50 μM A-769662 (30 min, 37 °C). Scale bars: 26 μm.
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α-subunit
To test how hBCK is recognized by AMPK, we applied a cytosolic
yeast two-hybrid assay (cyto-Y2H). This in vivo interaction assay is
very sensitive and can detect also weak or transient interactions. Its
speciﬁcity was veriﬁed by the dimerization of the hBCK monomer
(positive control) and hBCK interaction with Simian virus Large T
antigen (negative control; Fig. 2). The assays clearly revealed interaction
of hBCKWTwith constitutively active AMPK α2T172D (α2TD), but not
with inactiveWTα1 orα2 subunits, while the S6Dmutation prevented
any formation of BCK/AMPK complexes (Fig. 2). The AMPK β subunits
did not interact with hBCK neither. AMPK/BCK interactions were not
detectable by co-immunoprecipitation (data not shown). Thus, AMPK
substrate recognition is transient and requires activated AMPK α
subunits and non-phosphorylated BCK.3.4. S6D mutation or BCK phosphorylation do not alter enzymatic activity
We ﬁrst examined whether BCK phosphorylation modiﬁes its con-
formation or enzymatic activity. hBCK WT, S6D mutant and S6D/T35D
double mutant were analyzed by calibrated gel ﬁltration chromatogra-
phy. This revealed only BCK species at a size of about 86 kDa, conﬁrming
that the dimeric quaternary structure of hBCK is preserved in phospho-
mimetic mutants (Fig. 1G). However, a small shift to larger Stokes radii
in S6D mutant proteins indicated a slight conformational change. We
further determined the precise kinetic parameters of recombinant
hBCK WT and S6D mutant in both, forward and reverse directions ofthe two-substrate reaction (Table 2). The S6D mutation did not signiﬁ-
cantly alter enzyme kinetics in either direction of the reaction, and nei-
ther total speciﬁc activity, nor afﬁnity values for the substrates,
including Km (binding as ﬁrst substrate) and Kd (binding as second sub-
strate). The same was observed with BCK that was phosphorylated
in vitro by CamKKβ (data not shown) or with BCK isolated from
mouse astrocyte cultures after pharmacological AMPK activation
(Fig. 3D).
3.5. BCK is phosphorylated at Ser6 in astrocytes treated with A-769662 or
AICAR
To further examine enzyme activity-independent functions of phos-
phorylated BCK, we developed a polyclonal rabbit antibody speciﬁc for
the Ser6-phosphorylation of BCK (Fig. 3A). This antibody detected phos-
phorylated hBCK in immunoblots at high speciﬁcity, without cross-
reactivity to non-phosphorylated BCK (up to 6 μg enzyme) or other pro-
teins in immunoblots, and with a detection limit of about 400 ng hBCK.
BCK phosphorylation by AMPK in vivowas then examined in prima-
rymouse cortical astrocytes. These cells have high and ﬂuctuating ener-
gy demands and thus express elevated levels of BCK [33]. Astrocyte
AMPKwas activatedwith the pharmacological, cell-permeable activator
A-769662 (Abbott Laboratories). Already 30min treatment with 50 μM
A-769662 led to strong AMPK activation via αThr172 phosphorylation
in whole cell lysates (Fig. 3B). Using the anti-P-Ser6 BCK antibody, we
detected a concomitant appearance of a single band of phospho-Ser6
murine BCK in whole cell extracts, which was absent in untreated con-
trols. To conﬁrm an AMPK-dependent phosphorylation of BCK in cells
in vivo, we used AICA-riboside (AICAR) as a second pharmacological
Fig. 7. Astrocyte P-Ser6 BCK fully co-localizes with endoplasmic reticulum in confocal 3D-analysis. 3D-reconstruction of primary mouse astrocytes, treated for 30min with (A–C) vehicle
only (dH2O) or (D–F) 1 mM AICAR, and stained for (A,D) P-Ser6 BCK (red) or (B,E) ERmarker protein disulﬁde isomerase (PDI, green); (C,F) merged signals. These images are represen-
tative ofﬁve randomly chosenﬁelds, for eachofwhich a stack of nine confocal sectionswas obtained (z-series) using 0.5 μmstepwidth per plane (a gallery is shown in Suppl. Fig. S4). (G,I)
Merged pictures of the entire z-stack. (H,K) Correlation analysis of all z-stacks for both ﬂuorescence channels (scatter diagram; for details see Material and methods). (L) Fluorescence
intensity ratio of the red channel to the green channel as ameasure of P-Ser6 BCK signal increase relative to PDI. (M) Co-localization coefﬁcient for the red and green channels as ameasure
of P-Ser6 BCK/PDI co-localization, determined from Fig. 6H,K; data given as mean ± SD (n = 5), *p b 0.001. Scale bar: 26 μm.
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Fig. 8. Fibroblast P-Ser6 BCK co-puriﬁes with ER and co-localizes with ER calcium pump.
Immortalized mouse embryonic ﬁbroblasts were treated for 30 min with vehicle only
(dH2O) or 1 mM AICAR. (A) Cellular subfractionation revealing increased co-puriﬁcation
of murine BCK with ER-enriched postmitochondrial fraction after AICAR-treatment.
Crude homogenate, mitochondrial and post-mitochondrial fractions were subjected to
SDS-PAGE-immunodetection for mitochondrial voltage-dependent anion channel
(VDAC), plasmamembraneNa+/K+-ATPase, P-Ser6 BCK (P-BCK), and sarcoplasmic/endo-
plasmic reticulum Ca2+-ATPase 2 (SERCA). Representative blots of two independent ex-
periments. For further details see Material and methods. (B–D) Proximity ligation assay
revealing co-localization of P-Ser6 murine BCK with sarcoplasmic/ER Ca2+-pump
(SERCA). Mouse embryonic ﬁbroblasts (MEFs) treated for 30 min with (B) vehicle only
(dH2O) or (C) 1 mMAICAR, labeled with anti-P-BCK and anti-SERCA2 antibodies, and fur-
ther processed with the proximity ligation assay duolink kit (red ﬂuorescence). Nuclei
were stained with 1 μM Hoechst (blue ﬂuorescence). Images are representative of three
randomly chosen ﬁelds. Scale bar: 31 μm. (D) Ratio of red ﬂuorescence normalized to
cell number (number of nuclei), which corresponds to the amount of P-Ser6 BCK co-
localizing with SERCA2. Images were analyzed with Image J and Volocity software; data
are given as mean ± SD (n = 3), *p b 0.01.
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mouse primary astrocyteswith 1mMAICAR for 30min also led to phos-
phorylation of AMPK (at αThr172) and its direct substrate ACC (at
Ser79; Fig. 3C). 2D-PAGE protein separations revealed three equally
spaced P-Ser6 BCK spots with the same Mr, not seen in controls. Thus,
Ser6 phosphorylation of BCK occurs in astrocytes in vivo and is present
in different murine BCK species, likely differing by additional (auto)
phosphorylation events.
3.6. Ser6-phosphorylated BCK localizes to central, perinuclear cellular
regions
In search of a function for AMPK-mediated phosphorylation of BCK,
we investigated putative effects on murine BCK subcellular localization
by immunocytochemistry and confocal microscopy in the astrocyte
model (Fig. 4). Indeed, while untreated astrocytes presented only low
levels of P-Ser6 BCK (Fig. 4A), AMPK activation by two different phar-
macological activators (AICAR and A-769662) led to the appearance of
P-Ser6 BCK in the cell center, including the perinuclear region (Fig. 4B,
C). Bulk BCK in astrocytes is quite homogeneously distributed within
the cytosol, with some enrichment close to the plasma membrane and
in the many unbranched cellular processes (Fig. 4G). Activation of
AMPK by AICAR or A-769662 changed this distribution only slightly byincreasing the peripheral signals, but also inducing some faint peri-
nuclear staining (Fig. 4H,I, see white arrows). This suggests that P-
Ser6 BCK represents only a minor fraction of bulk cytosolic BCK.
To verify the speciﬁcity of anti-P-Ser6 antibody in these in vivo appli-
cations, two different control experiments were performed. First, we
applied a competition assay with the P-peptide that had been used for
the generation of the anti-P-Ser6 antibody. This led to an almost
complete disappearance of the P-Ser6 BCK signal (Fig. 4D–F). Second,
we used immortalized mouse embryonic ﬁbroblasts (MEF) derived
from BCK/AK1 double knock-out animals (BAK−/−MEF) [33]. WT
and BAK−/−MEFs at conﬂuence were treated with A-769662, which
activated AMPK in less than 30 min as detected by αThr172 phosphor-
ylation (Fig. 5). Immunostaining with anti-P-Ser6 antibody under the
very same conditions as for astrocytes revealed a similar central,
perinuclear staining in WT MEFs that increased with A-769662 treat-
ment (Fig. 5A,B). The BAK−/−MEFs analyzed under identical condi-
tions did not show any immunoﬂuorescence, neither in control nor in
A-769662-treated conditions (Fig. 5C,D). These experiments provide
clear evidence for the ﬂuorescence staining corresponding to Ser6-
phosphorylated murine BCK.
3.7. P-Ser6 BCK co-localizes with the endoplasmic reticulum
The deﬁned localization of murine BCK in perinuclear regions raised
the questionwhether the Ser-6 phosphorylated BCK species is bound to
a speciﬁc subcellular structure. Therefore, cellular co-localization of
BCK with different marker proteins in vivo was studied by confocal
microscopy in the primary mouse cortical astrocytes treated with A-
769662 or AICAR. Mitochondria and Golgi apparatus are capable to
bind small fractions of BCK ([59] and Schlattner et al., unpublished
data) and to show perinuclear localization. However, marker proteins
for both, mitochondria and Golgi, showed only minimal or incomplete
cellular co-localization with phosphorylated BCK (Fig. 6). Only protein
disulﬁde-isomerase (PDI), an ER marker, seemed to fully co-localize
with P-Ser6 BCK in confocal 3D-analysis (Fig. 7A–F). Correlation analysis
of the two ﬂuorescence channels conﬁrmed strong overlap of both
signals (Fig. 7G–K) with very good correlation (Fig. 7M), suggesting
that P-Ser6 BCK and PDI indeed co-localize. The 3D data also conﬁrmed
the AICAR-induced increase in P-Ser6 BCK which was about 8-fold
(Fig. 7L).
Since such confocal analysis is biased by the resolution limits of con-
focal microscopes, we aimed at additional evidence for close co-
localization of P-Ser6 BCK and ER in MEFs. First, we performed classical
cellular sub-fractionation of MEFs. In post-mitochondrial fractions
enriched for SERCA-containing ER membranes, P-Ser6 BCKwas present
at low but detectable amounts, and increased upon AICAR treatment
(Fig. 8A). Second, we used a proximity ligation assay (PLA) that detects
epitopes at a maximal distance of 30–40 nm.When applying antibodies
against P-Ser6 BCK and the sarcoplasmic/endoplasmic Ca2+-ATPase
SERCA in such PLA experiments, we could detect a signiﬁcant increase
of the ﬂuorescence signal after AICAR-treatment (Fig. 8B–D). Collective-
ly, these data identify the ER as the location of P-Ser6 BCK.
4. Discussion
The brain-type isoformof creatine kinase, BCK, has been identiﬁed in
this study as a novel AMPK substrate in vitro and in vivo. Native BCK
interacts with active AMPK, leading to BCK phosphorylation at one
main site determined to be Ser6. This post-translational modiﬁcation
leaves BCK enzyme activity unaffected, but leads a pool of P-BCK located
at ER membranes.
Phosphorylation of CK isoforms, including BCK, has been repeatedly
reported in earlier literature [36–38]. More recent proteomics studies
suggested speciﬁc phosphorylation sites for other CK isoforms, includ-
ing Ser128 in MCK, possibly targeted by protein kinase C (PKC) [60],
Ser319, Ser343, and Thr361 in sMtCK [61], and Tyr115 in uMtCK [62].
Fig. 9. Localization of the Ser6 phosphosite within the BCK dimeric structure. The high resolution chicken BCK structure [21] is shown in backbone representation with schematic second-
ary structure elements. (A) Banana-shaped BCK dimerwithmonomer A in yellow andmonomer B in cyan, (B) Close-up of the N-termini at themonomer/monomer interface. Ser6 is rep-
resented in CPK representation. Note the divergent N-termini in the twomonomers, withmonomer B folding inwards thus shielding Ser6 from the surface. (C) Close-up of panel B, rotated
by 90° to view the convex side of the dimer. Note: exposure of the hydroxyl function of Ser6 in monomer B. Figure prepared from PDB ID 1QH4 with WebLab ViewerPro 4.0.
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phorylation stoichiometries, or the resulting functional changes ismost-
ly lacking. In addition, CKs undergo autophosphorylation at multiple
residues close to their active site, albeit at very low stoichiometries
and without major effects on enzyme catalysis [63,64]. This alone
could account for many phosphorylation events as e.g. described for
MCK in hibernating mammals [65], frog muscle [66] or the diabetic
heart [61]. More speciﬁcally, PKC was reported to phosphorylate BCK
[37,67] and MCK [68,69], but phosphosites were never identiﬁed and
the physiological relevance remains elusive. Similarly, AMPK was re-
ported to phosphorylate and inhibit MCK, while vice versa active MCK
by maintaining high PCr/Cr ratios would inhibit AMPK [40]. However,
these regulations were not conﬁrmed by follow-up studies [41–43].
In the present study, we present in vitro and in vivo evidence for BCK
phosphorylation by AMPK that involves a different type of regulation.
Originating from a non-biased screen [46,47] that already led to con-
ﬁrmed novel AMPK substrates [70], we could identify Ser6 as the BCK
phosphosite. This site is conserved across vertebrate species and
shows phosphorylation kinetics and stoichiometries that compare fa-
vorablywith the reference AMPK substrate ACC, suggesting a conserved
physiological role of this phosphorylation. Although the Ser6 site does
not exactly ﬁt the stringent consensus motif for AMPK [45], it conforms
reasonablywell to residues identiﬁed in a peptide library proﬁling for an
optimal AMPK phosphorylation motif [71]. Comparison of BCK phos-
phorylation levels with those of ACC suggests one phosphorylation per
BCK dimer. This could be verywell explained by themolecular structure
of BCK that we solved over ten years ago [21]. Although BCK always
occurs in homodimeric form, it folds into a structural heterodimer
(Fig. 9A). Only one monomer exposes its N-terminus at the convex
side of the banana-shaped dimer, while the N-terminus of the second
monomer folds back into the monomer/monomer interface (Fig. 9B,C).
Thus, effectively only one Ser6 per BCK dimer is accessible for AMPK
phosphorylation. Our Y2H interaction data further suggest a sequence
of events leading to BCK phosphorylation, in which AMPK is ﬁrstactivated to interact with BCK. As soon as BCK is phosphorylated by
bound AMPK, this will trigger its detachment from AMPK, independent
of the AMPK phosphorylation state. Since AMPK/BCK interaction can
only be detected by Y2H assays and not by co-immunoprecipitation, it
is of rather low afﬁnity and rapid ‘kiss-and-run’ character.
Earlier studies on putative CK phosphorylation tested mainly for en-
zymatic activity. They reported inhibitions up to 50%, as e.g. for PKC- or
AMPK-phosphorylatedMCK [40,60]. However, 31P NMR spectroscopy of
intact rat heart revealed that at increased workload, MCK activity is
rather increased than decreased, and positively correlates with higher
AMP levels and AMPK activity [41–43]. In the present study, we neither
observed any signiﬁcant change in the catalytic properties of phospho-
mimetic BCK S6D mutant or BCK in AMPK-activated astrocyte cultures.
Generally, it may also be questionedwhetherminor activity changes re-
ported in earlier studies would be sufﬁcient to effectively regulate this
high turnover enzyme in vivo. At least heterozygous CK knockout ani-
mals with gradually reduced CK levels have no obvious phenotype [72].
Effects of BCK phosphorylation at a subcellular level have not yet
been addressed. Only recently, interaction of MCK with the plasma
membrane Na+/Ca2+ exchanger has been reported to depend on a
putative Ser128 phosphorylation of MCK [69]. In the present study, we
analyzed subcellular localization of phospho-BCK in mouse astrocytes
and ﬁbroblasts treated with two mechanistically different pharmaco-
logical AMPK activators, AICAR or A-769662, and using confocalmicros-
copy, cell fractionation and PLA assays with a speciﬁc anti-P-Ser6 BCK
antibody. Taken together, the results show that (i) detection of
phospho-BCK by anti-P-Ser6 antibody is highly speciﬁc as seen with
transgenic MEFs lacking BCK, (ii) basic levels of phospho-BCK are low
in astrocytes and ﬁbroblasts, (iii) a speciﬁc BCK pool is phosphorylated
in both cell types after activation of AMPKwith the two different activa-
tors, and (iv) phospho-BCK localizes to the ER close to the SERCA Ca2+-
pump. These data suggest that, during energy stress activating AMPK, a
pool of BCK becomes phosphorylated that is localized to the ER. Phos-
phorylation may trigger recruitment of soluble BCK to the ER, although
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by a highly localized action of AMPK. In either case, BCK phosphoryla-
tion could trigger interaction events via the change in charge and/or
the observed small conformational changes. Ser6 phosphorylation is
well located at the convex side of the BCK dimer to engage into interac-
tionswithout disturbing the active sites located at the opposite, concave
side of the dimer (Fig. 9A). The Ser6-site is also close to the domain
which in homologous MCK mediates binding to myomesin and M-
protein in the myoﬁbrillar M-band [28,29]. Unfortunately, the anti-P-
Ser6 antibody is not applicable for co-immunoprecipitation to isolate in-
teraction partners, and future studies will have to identify mechanisms
and receptor(s) involved in the BCK/ER interaction.
Speciﬁc subcellular localization of BCK has been reported in astro-
cytes for peripheral regions and pseudopodia, where the enzyme asso-
ciates with the cytoskeleton and thus contributes to cell shape and
motility [33]. BCK also binds to and activates membrane-associated
thrombin receptor PAR-1 [35] and a K+/Cl− cotransporter [73] at the
plasma membrane, and transiently interacts with cis–Golgi matrix pro-
tein [59]. At all these speciﬁc sites, BCK is expected to locally regenerate
ATP for nearby energy-dependent processes. This is particularly impor-
tant close to membranes, where ATP diffusion may become limiting
much earlier during energy stress. We thus propose that BCK phos-
phorylation is a molecular mechanism to recruit BCK into micro-
compartments at the ER membrane to sustain ATP-requiring
reactions. These may include SERCA that we found co-localized with
BCK and for which functional interaction is well established for the
highly homologous MCK [74–76]. It can be envisaged that cytosolic
Ca2+-overload as occurring under energy-compromised conditions ac-
tivates the CamKKβ–AMPK signaling cascade to phosphorylate BCK.
This could favor interactions bringing BCK in close vicinity of SERCA to
support its activity, thus reducing cytosolic Ca2+-overload. ATP con-
sumption by SERCAs may represent up to 20% of whole body total
daily energy expenditure [77] and SERCA function strongly depends
on a high local ATP/ADP ratio that can be maintained by CK. In support
of this model, SERCA activity is reduced in AMPK α2−/− endothelial
cells and can be restored by expressing constitutive active AMPK [78].
However, also other functions of ER-based ATP regeneration are con-
ceivable, as e.g. supporting the recently described calcium- and AMPK-
controlled ATP-inﬂux into the ER lumen [79].
In conclusion, we have identiﬁed a post-translational regulation of
BCK by AMPK that involves ER localization. Further investigations are
required to determine its importance for ER functions under energy
stress in vivo.
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